Resolution Therapeutics is developing macrophage cell therapies to treat inflammatory and fibrotic diseases, including liver cirrhosis, by utilizing engineered macrophages to promote organ repair and reduce the need for transplants. Their proprietary platform focuses on macrophage biology and manufacturing processes to deliver targeted therapeutic solutions for patients suffering from life-threatening organ damage.
Funding
$134M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Inflammatory and fibrotic diseases cause life-threatening organ damage, often leading to the need for organ transplantation. Current treatments are limited in their ability to promote organ repair and resolve inflammation effectively.
Solution
Resolution Therapeutics is developing macrophage cell therapies designed to treat inflammatory and fibrotic diseases, with an initial focus on liver cirrhosis. The company engineers macrophages to promote organ repair and reduce the need for transplants. Their approach leverages a proprietary platform encompassing macrophage biology, cell engineering, and manufacturing processes to deliver targeted therapeutic solutions. By harnessing the body's natural wound-healing mechanisms, Resolution aims to improve outcomes for patients suffering from life-threatening organ damage.
Target Audience
The primary target audience includes patients with inflammatory and fibrotic diseases, particularly those with liver cirrhosis, and the healthcare providers who treat them, such as hepatologists and transplant surgeons.
Features
- Engineered macrophage cell therapies for targeted treatment of inflammatory and fibrotic diseases.
- Proprietary platform based on macrophage biology, cell engineering, and manufacturing processes.
- Focus on promoting organ repair and reducing the need for transplantation.
- RTX001 is in Phase 1/2 clinical trials for end-stage liver disease.